Transcription factor STAT3 has been shown to regulate genes that are involved in stem cell selfrenewal and thus represents a novel therapeutic target of great biological significance. However, many small molecule agents with potential effects in cancer therapy lack aqueous solubility and high off-target toxicity, hence impeding efficient bioavailability and activity. This work, for the first time, reports a prodrug-based strategy for selective and safer delivery of STAT3 inhibitors designed towards metastatic and drug resistant breast cancer. We have synthesized a novel lipaselabile SN-2 phospholipids-pro-drug from a clinically investigated STAT3 inhibitor, nifuroxazide (Pro-nifuroxazide), which can be regioselectively cleaved by the membrane abundant enzymes in *